A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

NCT03797456 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

MZL

Interventions

DRUG: ICP-022

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.